Your NEJM Group Today: Diabetic Foot Ulcer Recurrence / Capecitabine & Postsurgical Residual Breast Cancer / Colorado Cardiology Opportunity — Physician’s First Watch

Medical News |
June 19, 2017

Your NEJM Group Today: Diabetic Foot Ulcer Recurrence / Capecitabine & Postsurgical Residual Breast Cancer / Colorado Cardiology Opportunity

By the Editors

Here's what we chose for you from NEJM Group today:

NEJM Clinical Practice Center: Review: Foot ulceration is the most common lower-extremity complication in patients with diabetes mellitus. This review considers the pathogenesis, treatment, and management of diabetic foot ulcers, including prevention of recurrence.

NEJM Journal Watch Oncology and Hematology: Capecitabine may reduce the risk for relapse in breast cancer patients who have residual disease following preoperative chemotherapy.

NEJM CareerCenter: Denver Health Medical Center, together with the University of Colorado School of Medicine, is recruiting for a Division Head of Cardiology to join their collaborative and collegial team of physicians in Denver, Colorado.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.